Royal Numico/Rexall Sundown Eyes Private Label As Key Growth Area

Combined Royal Numico/Rexall Sundown operations regard their potential for private label sales in the U.S. mass market to be "very high," the firms reported during a May 1 teleconference. Numico and Rexall have little presence in U.S. private label now but appear to be pondering it for the future despite the traditional low margins of the products.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet